MX2009012316A - Metodos de tratamiento de trastornos cognitivos mediante la inhibicion de gpr12. - Google Patents
Metodos de tratamiento de trastornos cognitivos mediante la inhibicion de gpr12.Info
- Publication number
- MX2009012316A MX2009012316A MX2009012316A MX2009012316A MX2009012316A MX 2009012316 A MX2009012316 A MX 2009012316A MX 2009012316 A MX2009012316 A MX 2009012316A MX 2009012316 A MX2009012316 A MX 2009012316A MX 2009012316 A MX2009012316 A MX 2009012316A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- gprl2
- hippocampal
- performance
- gpr12
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente invención provee métodos para proyectar un agente farmacéutico para su habilidad para modular la formación de memoria a largo plazo, ejecutar una tarea cognitiva que depende del hipocampo o función de Gpr12. La presente invención también provee métodos para modular la formación de memoria a largo plazo o desempeño de una tarea cognitiva que depende del hipocampo mediante la modulación de la expresión de la proteína que depende de Gpr12. La presente invención además provee métodos para tratar un defecto en la formación de memoria a largo plazo mediante la inhibición de la función de Gpr12 y métodos para tratar un defecto en el desempeño de una tarea cognitiva que depende del hipocampo mediante la inhibición de la función de Gpr12.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93816307P | 2007-05-15 | 2007-05-15 | |
| PCT/US2008/063804 WO2008144453A1 (en) | 2007-05-15 | 2008-05-15 | Methods of treating cognitive disorders by inhibition of gpr12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009012316A true MX2009012316A (es) | 2009-12-03 |
Family
ID=40122145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009012316A MX2009012316A (es) | 2007-05-15 | 2008-05-15 | Metodos de tratamiento de trastornos cognitivos mediante la inhibicion de gpr12. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7968524B2 (es) |
| EP (1) | EP2162137B1 (es) |
| JP (1) | JP2010527375A (es) |
| KR (1) | KR20100029079A (es) |
| CN (1) | CN101808647A (es) |
| AU (1) | AU2008254905A1 (es) |
| BR (1) | BRPI0811625A2 (es) |
| CA (1) | CA2684920A1 (es) |
| IL (1) | IL202091A0 (es) |
| MX (1) | MX2009012316A (es) |
| WO (1) | WO2008144453A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102458435A (zh) | 2009-04-09 | 2012-05-16 | 考格尼申治疗股份有限公司 | 认知衰退的抑制剂 |
| WO2011014880A1 (en) | 2009-07-31 | 2011-02-03 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
| WO2011106785A2 (en) * | 2010-02-26 | 2011-09-01 | Cognition Therapeutics, Inc. | Methods of identifying agents effective to treat cognitive decline and diseases associated therewith |
| JP2014511373A (ja) | 2011-02-02 | 2014-05-15 | コグニション セラピューティクス インク． | ウコン油から単離された化合物およびその使用方法 |
| US9796672B2 (en) | 2014-01-31 | 2017-10-24 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| MX2019013524A (es) | 2017-05-15 | 2020-02-10 | Cognition Therapeutics Inc | Composiciones para tratar enfermedades neurodegenerativas. |
| BR102022009685A2 (pt) * | 2022-05-18 | 2023-11-28 | Fundação Oswaldo Cruz | Método para triagem de fármacos ou substâncias com potencial neuroprotetor, kit para triagem de fármacos ou substâncias, e, uso de um painel de genes |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69424406T2 (de) * | 1993-02-19 | 2000-10-26 | Nippon Shinyaku Co., Ltd. | Arzneistoffzusammensetzung, die ein nukleinsäurecopolymer enthält |
| US6291438B1 (en) * | 1993-02-24 | 2001-09-18 | Jui H. Wang | Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use |
| US5858988A (en) * | 1993-02-24 | 1999-01-12 | Wang; Jui H. | Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use |
| US5877399A (en) * | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| ATE386131T1 (de) * | 1994-04-13 | 2008-03-15 | Univ Rockefeller | Aav-vermittelte überbringung von dna in zellen des nervensystems |
| US5684143A (en) * | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
| US6653086B1 (en) * | 1998-04-14 | 2003-11-25 | Arena Pharmaceuticals, Inc. | Endogenous constitutively activated G protein-coupled orphan receptors |
| AU5787901A (en) * | 1999-12-10 | 2001-07-09 | Astrazeneca Ab | Compound |
| US20040224316A1 (en) * | 2000-08-10 | 2004-11-11 | Tully Timothy P. | Augmented cognitive training |
| US20060247194A1 (en) * | 2000-08-30 | 2006-11-02 | Sirna Therapeutics , Inc. | Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina) |
| WO2002044321A2 (en) * | 2000-12-01 | 2002-06-06 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Rna interference mediating small rna molecules |
| US6586524B2 (en) * | 2001-07-19 | 2003-07-01 | Expression Genetics, Inc. | Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier |
| US20040023384A1 (en) * | 2002-07-31 | 2004-02-05 | Isis Pharmaceuticals Inc. | Antisense modulation of G protein-coupled receptor 12 expression |
| US20050106731A1 (en) | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
| US8729036B2 (en) * | 2002-08-07 | 2014-05-20 | University Of Massachusetts | Compositions for RNA interference and methods of use thereof |
| WO2004038407A2 (en) * | 2002-10-24 | 2004-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12) |
| US7829694B2 (en) * | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
| US20070104688A1 (en) * | 2003-02-13 | 2007-05-10 | City Of Hope | Small interfering RNA mediated transcriptional gene silencing in mammalian cells |
| JP2007505617A (ja) * | 2003-09-19 | 2007-03-15 | パラダイム・セラピューティクス・リミテッド | 受容体 |
| EP1745295B1 (en) * | 2004-04-20 | 2010-10-06 | Galapagos N.V. | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
-
2008
- 2008-05-15 KR KR1020097024747A patent/KR20100029079A/ko not_active Application Discontinuation
- 2008-05-15 CN CN200880023965A patent/CN101808647A/zh active Pending
- 2008-05-15 WO PCT/US2008/063804 patent/WO2008144453A1/en active Application Filing
- 2008-05-15 MX MX2009012316A patent/MX2009012316A/es unknown
- 2008-05-15 BR BRPI0811625-3A2A patent/BRPI0811625A2/pt not_active IP Right Cessation
- 2008-05-15 EP EP08755619.7A patent/EP2162137B1/en not_active Not-in-force
- 2008-05-15 CA CA002684920A patent/CA2684920A1/en not_active Abandoned
- 2008-05-15 AU AU2008254905A patent/AU2008254905A1/en not_active Abandoned
- 2008-05-15 JP JP2010508596A patent/JP2010527375A/ja active Pending
- 2008-05-15 US US12/121,731 patent/US7968524B2/en not_active Expired - Fee Related
-
2009
- 2009-11-12 IL IL202091A patent/IL202091A0/en unknown
-
2011
- 2011-06-27 US US13/169,739 patent/US20110281936A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100029079A (ko) | 2010-03-15 |
| US7968524B2 (en) | 2011-06-28 |
| BRPI0811625A2 (pt) | 2014-11-11 |
| EP2162137B1 (en) | 2016-11-23 |
| EP2162137A4 (en) | 2011-06-08 |
| US20110281936A1 (en) | 2011-11-17 |
| IL202091A0 (en) | 2010-06-16 |
| AU2008254905A1 (en) | 2008-11-27 |
| CA2684920A1 (en) | 2008-11-27 |
| WO2008144453A9 (en) | 2010-03-18 |
| CN101808647A (zh) | 2010-08-18 |
| US20090022667A1 (en) | 2009-01-22 |
| WO2008144453A1 (en) | 2008-11-27 |
| EP2162137A1 (en) | 2010-03-17 |
| JP2010527375A (ja) | 2010-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009012316A (es) | Metodos de tratamiento de trastornos cognitivos mediante la inhibicion de gpr12. | |
| MX2007011859A (es) | Compuestos mejorados farmacocineticamente. | |
| WO2007071448A3 (en) | Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation | |
| MX2020011792A (es) | Anticuerpos monoclonales contra claudina-18 para el tratamiento de cancer. | |
| MX2009012906A (es) | Anticuerpos monoclonales contra claudin-18 para tratamiento de cancer. | |
| SG10201405377XA (en) | Compositions and methods for antibodies targeting complement protein c5 | |
| MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
| WO2009064920A3 (en) | Compounds and methods for modulating protein expression | |
| UA101478C2 (ru) | Соединения, полезные как ингибиторы raf-киназы | |
| SG166813A1 (en) | 5-lipoxygenase-activating protein (flap) inhibitors | |
| MA28702B1 (fr) | Composes et procedes pour l'inhibition de l'interaction de proteines bcl avec des partenaires de liaison | |
| SG165387A1 (en) | 5-lipoxygenase-activating protein (flap) inhibitors | |
| WO2008033408A3 (en) | Methods for identifying compounds that modulate cell signaling and methods employing such compounds | |
| TN2009000521A1 (en) | Rnai inhibition of alpha-enac expression | |
| MX2009003981A (es) | Agentes moduladores del receptor de calcio. | |
| EP2101772A4 (en) | NEUROMUSCULAR BLOCKAGE AGENTS WITH INTERMEDIATE DURATION AND THEIR ANTAGONISTS | |
| MX2010004615A (es) | Anticuerpos monoclonales contra proteina c. activada e inactivada. | |
| NO20093542L (no) | Inhibering av tumormetastase ved hjelp av anti-neuropilin 2-antistoffer | |
| GEP20125586B (en) | Novel method for synthesis of (7-methoxy-l-naphthyl)-acetonitrile and application thereof in synthesis of agomelatine | |
| PL1987357T3 (pl) | Polipeptydy rozpoznawane przez przeciwciała anty-Trichinella oraz ich zastosowanie | |
| MX2008012208A (es) | Metodo para tratar trastornos cognitivos y otros afines. | |
| WO2009015369A3 (en) | Isophthalamide derivatives inhibiting beta-secretase activity | |
| TW200621744A (en) | Mercaptoamides as histone deacetylase inhibitors | |
| MX2012001999A (es) | Uso de inhibidores nkg2d para tratar enfermedades cardiovasculares y metabolicas, tal como diabetes tipo 2. | |
| WO2007092471A3 (en) | Methods for inhibition of lymphangiogenesis and tumor metastasis |